Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin.

Daniele CaraccioloGiada JuliCaterina RiilloAdriana CoricelloFrancesca VasileSara PollastriRoberta RoccaFrancesca SciontiNicoletta PoleràKatia GrilloneMariamena ArbitrioNicoletta StaropoliBasilio CaparelloDomenico BrittiGiovanni LopreteGiosuè CostaMaria Teresa Di MartinoStefano AlcaroPierosandro TagliaferriPierfrancesco Tassone

Published in: Journal of translational medicine (2022)

Taken together, our findings provide proof of concept that RHM targets LIG3 addiction in MM and may represent therefore a novel promising anti-tumor natural agent to be investigated in an early clinical setting.

Keyphrases

multiple myeloma
circulating tumor
cell free
single molecule
nucleic acid
high resolution